The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|April 18, 2017
Nuances in Treating Squamous Cell Lung Cancer: Case 1
Nuances in Treating Squamous Cell Lung Cancer
Advertisement
April 2013
- A 72-year-old female presented to her primary care physician with symptoms of shortness of breath and increased cough.
- The patient has a 40-year (1 pack/day) smoking history.
- Chest X-Ray revealed a right upper lobe opacity.
- CT of the chest and abdomen showed a 3 cm. right upper lobe mass, pleural thickening, and a left adrenal gland nodule.
- She underwent core needle biopsy, the left adrenal mass showed squamous cell carcinoma that was p40+ and p63+.
- PET/CT indicated stage IV squamous cell lung cancer.
- The patient began chemotherapy with carboplatin/nab-paclitaxel.
- CT after 2 cycles of therapy indicated that her tumor burden decreased significantly. At that point the patient reported improvement of her symptoms.
- After 6 cycles the patient had stable disease.
October 2015
- Routine follow up imaging showed a new left upper lobe mass of 2 cm.
- The lung lesion was biopsied and confirmed to be of squamous cell histology.
- Based on multidisciplinary assessment, the new lung lesion was treated with stereotactic radiosurgery.
June 2016
- The patient reported symptoms of coughing and shortness of breath.
- CT showed increased diameter in both lung masses. The adrenal mass remained stable.
- The patient was subsequently started on nivolumab.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5